Tango Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

March 6, 2023

https://www.globenewswire.com/news-release/2023/03/06/2620911/0/en/Tango-Therapeutics-Announces-Inducement-Grants-Under-Nasdaq-Listing-Rule-5635-c-4.html

BOSTON, March 06, 2023 (GLOBE NEWSWIRE) — Tango Therapeutics, Inc. (NASDAQ:TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, today announced that, effective March 1, 2023, the Compensation Committee of Tango Therapeutics’ Board of Directors granted non-qualified stock options to purchase an aggregate of 637,000 shares of its common stock and an aggregate of 106,250 restricted stock units (RSUs) to two new employees under Tango Therapeutics’ 2023 Inducement Plan; including 487,500 stock options and 81,250 RSUs to Adam Crystal, M.D., Ph.D. in connection with his acceptance of employment as Tango Therapeutics’ President of Research and Development.

Read more at globenewswire.com

Related news for (TNGX)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.